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Background. National guidelines prompted the implementation of a designated two-week wait referral pathway to facilitate the
early diagnosis of sarcomas, to improve treatment outcomes. Methods. Patients referred to the Cambridge Sarcoma Diagnostic
Clinic between January 2013 and December 2014 were identified through the electronic appointments system. Information was
retrospectively retrieved about patient characteristics and details of the diagnostic pathway. Results. 17.3% of patients referred
(69/397) were diagnosed with amalignancy. Of these, 59.3% (41/69) had primary sarcomas, 17.4% (12/69) hadmetastatic cancer, and
23.2% (16/69) had a different primary malignancy. 15% of the 41 sarcomas were <5 cm, 34% in the 5–10 cm range, and 51% >10 cm.
Sarcomas diagnosed through this clinic represented 13% (41/315) of sarcomas managed at the centre during the same 2 years.
Conclusion. While we achieved the target of 10% (41/397) sarcoma diagnosis rate in the rapid access clinic, only 15% of these were
<5 cm better prognosis lesions. This calls into question the “real world” impact of such diagnostic clinics on early diagnosis of
sarcomas. In order to enhance generic cancer diagnostic skills, training in these diagnostic clinics could be usefully integrated into
national training curricula for both surgical and nonsurgical oncologists.
1. Introduction
Approximately 2,700 bone and soft tissue sarcomas are
diagnosed each year in the UK, accounting for 1% of all
cancer diagnoses [1]. In 2000 the first comprehensive national
plan for investment and reform for cancer commissioned
by the government [2] had set out ambitious plans to cut
waiting times for diagnosis and treatment of all cancer types.
In the white paper [2], Chapter 5 called for the immediate
implementation of two-week maximum wait for an urgent
outpatient appointment for all suspected cancers.
Due to the comparative rarity, a diagnosis of sarcoma is
less commonly included in the differential by primary care
physicians. National guidelines [3, 4] prompted urgent two-
week wait (2ww) referrals to tertiary diagnostic centres for
patients with a soft tissue mass with any one of the following
features: (i) size > 5 cm; (ii) increasing in size; (iii) being
deep to deep fascia; (iv) being painful; (v) being recurrent
after previous excision. Patients with abnormal radiographic
findings suspicious for bone tumours were also to be referred
under the same 2ww rule.
The Improving Outcomes Guidance for Sarcoma [5]
states that “only one in ten referrals of ‘suspicious lumps’ will
be a sarcoma.” We performed an in-depth comprehensive
analysis of our diagnostic practice in order to determine its
impact on the early diagnosis of sarcoma.
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Table 1: Diagnostic pathways and results.
Method of diagnosis BT T I BE P M S SM Total
Local
Clinical 1 1 1 2 5
Excisional biopsy, plastic surgeon 84 5 12 1 4 106
Histology, colorectal surgeon 1 1
Histology, neurosurgeon 1 1 2
Histology, orthopaedics 1 2 3
Biopsy (radiology guided) 10 5 4 12 7 7 45
BMT 2 2
Radiological 74 16 20 60 3 1 173
Total 170 18 31 78 13 11 15 2 338
% (of all local) 50.29 5.32 9.17 23.07 3.84 3.25 4.43 0.59 100
Supraregional
Histology, Bham 14 1 2 21 2 43
Histology, Pworth 1 1 1 3 5
Radiological, Bham 6 4 2 10
Radiological, RMH 1 1
Total 22 1 4 3 1 26 2 59
% (of all supraregional) 7.28 1.69 0 6.77 5.08 1.69 44.06 1.69 100
All Total 192 19 31 82 16 12 41 4 397
% (of all) 48.36 4.78 7.80 20.65 4.03 3.02 10.32 0.75 100
BT: benign tumours, T: traumatic lesion, I: inflammatory/infective lesions, BE: benign lesions of nontumorous nature or no abnormality detected, P: primary
cancer, M: metastatic cancer, S: sarcoma, SM: semimalignant tumour, BMT: bone marrow trephine, Bham: Royal Orthopaedic Hospital Birmingham or the
Midland Abdominal and Retroperitoneal Sarcoma Unit (MARSU), Pworth: Papworth Hospital, and RMH:The Royal Marsden Hospital.
2. Methods
All patients referred under the 2ww rule to the Cambridge
SarcomaDiagnostic Clinic of the Cambridge University Hos-
pitals NHS Foundation Trust (CUHFT) between 1 January
2013 and 31 December 2014 were identified through the
electronic appointments system.The 2ww clinic with referral
proformas had been developedwithin theAngliaCancerNet-
work and started in January 2011. These were available to all
general practitioners (GPs) in the catchment area.The 2-year
period detailed in this paper therefore represents the 2ww
pathways in an established phase. Referrals weremade for any
soft tissue mass with one or more of the following established
characteristics: larger than 5 cm, painful, increasing in size,
deep to deep fascia, and recurring after previous excision or
for any bone lesions with radiological suspicion of a primary
bone tumour.
Each patient referred to our tertiary sarcoma centre had
a clinical review and an individualized diagnostic pathway
established. The outcomes of diagnostic investigations were
discussed in the local SarcomaMultidisciplinary TeamMeet-
ing (MDT) of CUHFT. All cases deemed suspicious for soft
tissue or bone sarcomawere referred for further discussion in
the designated site specificMDTof the Birmingham Sarcoma
Specialist Advisory Group (suspected bone sarcomas and
soft tissue sarcomas occurring in extremities to the Royal
Orthopaedic Hospital NHS Foundation Trust and all other
suspected soft tissue sarcomas to the University Hospitals
Birmingham NHS Foundation Trust). The supraregional
Birmingham Centres provided the surgical expertise of safe
tissue sampling in highly suspicious cases for sarcoma and
also the operativemanagement once a sarcoma diagnosis was
established (chemotherapy and radiotherapy as needed was
delivered in the designated Sarcoma Unit of CUHFT).
Once the patients were identified a database was cre-
ated retrospectively and the following data items were
retrieved (using paper and electronic patient records): patient
demographics, anatomical site and radiological size of the
mass, imaging investigations leading to diagnosis, method of
obtaining a diagnosis (radiological, histology, and clinical),
final diagnosis, and geographic site of diagnosis (local versus
supraregional surgical sarcoma centre).
3. Results
397 patients referred under the 2ww were reviewed in the
sarcoma fast-track diagnostic clinic of CUHFT as part of
the Cambridge Cancer Centre during the study period—188
patients in 2013 and 209 in 2014.
The mean age of patients was 56.1 years (range 16–
93) with a female :male ratio of 1.04 : 1. The most frequent
anatomical location of the suspected sarcoma was in the
thighs with 66 (16.6%) cases, followed by the chest wall (33
cases, 8.3%) and the shoulders (32 cases, 8%) (see Supplemen-
tary Table 1 in Supplementary Material available online at
http://dx.doi.org/10.1155/2016/6032606). In 338/397 (85.1%)
patients the diagnosis was established locally in Cambridge
and in 59/397 (14.9%) patients this was achieved at the
Sarcoma Specialist Advisory Group/MDT in Birmingham.
The final diagnosis was supported by histology results in
208/397 patients (52.4%). In 5 patients the diagnosis was
based solely on clinical grounds. In 178/397 (44.8%) patients
the final confirmatory diagnosis was based on the results of
imaging studies (Table 1).
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Table 2: Pattern of radiological investigations and malignancy detection rates.
Imaging modality All Measurable Average size (range) mm Metastatic cancer Primary cancer Sarcoma
US 64 54 33.55 (4–130)
MRI 61 54 48.33 (9–150) 1
CT 19 16 108.43 (24–200) 4 3 10
X-ray 6 0
US MRI 113 106 53.79 (8–154) 1
US CT 9 8 51.37 (12–150) 1 1 1
US X-ray 3 2 25 (10–40)
MRI CT 33 31 83.26 (20–250) 2 3 10
MRI X-ray 19 7 48.71 (18–110)
CT X-ray 2 0
CT NM 1 1 40
X-ray NM 1 0
US MRI CT 46 46 76.27 (18–222) 3 6 14
US MRI X-ray 4 2 35.5 (6–65)
MRI CT X-ray 6 6 67.50 (40–150) 1 2
MRI CT NM 3 3 86 (38–140) 1 2
MRI X-ray NM 1 0
US MRI X-ray CT NM 1 1 40 1
Did not attend US 1 0
No imaging required 4 0
Total 397 337 58.26 (4–250) 12 16 41
US: ultrasound, MRI: magnetic resonance imaging, CT: computed tomography, and NM: bone isotope scan.
A wide range of imaging tools and combinations thereof
were employed in order to achieve a diagnosis. 337/397
(84.9%) patients had objectively measurable lesions on radi-
ological examination; the average size of all lesions was
58.3mm (range 4–250). 239/397 (60.2%) patients had an US
and 287/397 (72.3%) an MRI, on their own or as part of
multiple imaging (Table 2).
192/397 (48.4%) patients were diagnosed with a benign
tumour.Themost frequently diagnosed benign tumours were
lipogenic in nature (124), followed in order of frequency
by neural lesions (21), vascular/lymphatic tumours (14),
fibromatous growth (12), and bone tumours (9) (Table 3).
7.8% of patients (31/397) had an inflammatory or infective
condition of some sort. 19 patients presented with a lesion
secondary to trauma and 14 patients were diagnosed with
cysts. Further 26 patients presented with “other” benign,
nontumourous conditions, including fat necrosis (8), bursa
(5), and endometriosis (4). No abnormality of any sort
was detected in 14 patients, while 28 patients had normal
anatomical variations/fatty lumpiness that resulted in their
“lumps or bumps” (Supplementary Table 2).
Four patients with a mean age of 50.2 years (range 37–61)
were diagnosed with a borderline tumour of 33mm (range
18–45) average size. Pathologies included a fibromyxoid
tumour, a giant cell tumour of tendon sheath, and two cases
of pigmented villonodular synovitis of the joint.
69/397 (17.4%) patients were diagnosed with cancer, more
specifically 41/397 (10.3%) with primary soft tissue or bone
sarcomas, 16/397 (4%) with other primary malignancies, and
12/397 (3%) with metastatic cancers. Of patients diagnosed
with malignancy bone or soft tissue sarcoma was the most
common diagnosis: 41/69 (59.4%) (Table 4). The average age
of patients diagnosed with a bone (4) or soft tissue (35) sar-
comawas 59.7 years, themean size of sarcomaswas 106.3mm.
The highest prevalence of detected sarcomas was in the thigh
(14), followed by retroperitoneum (4), pelvis (3), and chest
wall locations (3). The mean size of the four diagnosed
bone sarcomas was 98.5 (44–140) mm, while that of soft
tissue sarcomas was 110.21 (10–240) mm. At presentation 6/41
(14.6%) sarcomas were smaller than 5 cm and 14/41 (34.1%)
sarcomas were in the 5–10 cm range with the remaining 21/41
(51.2%) larger than 10 cm. The 4 retroperitoneal sarcomas
(3 liposarcomas and 1 sarcoma with rhabdomyosarcomatous
differentiation) were all larger than 10 cm. Excluding the
retroperitoneal sarcomas and the two GISTs, the mean size of
extremity and trunk wall soft tissue sarcomas was 102.62mm.
Liposarcomas (mainly atypical lipomatous tumours)
were the most frequently diagnosed sarcomas. The eight
atypical lipomatous tumours mainly affected the thighs (6)
with one case arising in the buttock and another one in the
retroperitoneum. 20 sarcomas were of high grade (grade 3)
at diagnosis. Seven patients had distant spread of disease at
presentation and a further 3 developed metastatic disease
within 1 year of primary diagnosis (Table 4). 29 patients
were treated with a radical curative intent, while in 10 cases
a palliative approach was followed from the diagnosis (6
patients being unsuitable for any active treatment). Eight
sarcoma patients have died since the diagnosis (Table 5).
In the two years reviewed here, a total of 314 patients
(151 in 2013 and 163 in 2014) were diagnosed with sarcoma
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Table 3: Diagnostic distribution of benign tumours.
Lipogenic tumours
Angiolipoma 7
Lipoma (simple) 86
Lipoma (intra-articular) 1
Lipoma (intramuscular) 12
Lipoma (multiple simple) 6
Lipoma (spindle cell) 8
Lipoma with fat necrosis 1
Lipomatosis 1
Angiomyolipoma 1
Fibrolipoma 1
Bone tumours
Benign giant cell tumour 1
Cystic medullary bone tumour 1
Enchondroma 3
Exostosis 1
Intraosseous ganglion 1
Osteochondroma 2
Neural tumours
Neural tumour 1
Neurofibroma 1
Neuroma benign 1
Peripheral nerve sheath tumour 4
Schwannoma 14
Vascular/lymphatic tumours
Angiomyofibroblastoma 1
Arteriovenous malformation 2
Glomus tumour 2
Haemangioma 6
Lymphangioma 1
Masson’s papillary endothelial hyperplasia 1
Venous malformation 1
Fibromatous tumours
Benign fibroelastoma 1
Desmoid-type fibromatosis 7
Fibroepithelial polyp 1
Fibrous dysplasia 1
Fibrovascular tissue 1
Plantar fibromatosis 1
Other
Ganglion 4
Granular cell tumour 1
Myxoma 5
Pilomatrixoma 1
Sarcoid, foreign body 1
Spiradenoma 1
and referred to the sarcoma team at CUHFT. Therefore only
41/314 (13%) of sarcoma patients were referred through the
fast-track diagnostic clinic.
In addition to the diagnosed sarcomas, 12/69 (17.4%)
had soft tissue lumps or bony abnormalities which were
shown on biopsy to be metastatic cancer from a different
primary source (Table 6) and 16/69 (23.2%) were diagnosed
with another primary malignancy. Of 28 nonsarcomatous
cancers (primary and metastatic) haematological malignan-
cies accounted for 50% (14/28) with 8 having lymphomas,
5 having plasmacytomas, and 1 having multiple myeloma
(Table 6). In addition, one patient was diagnosed with a
primary Merkel cell skin tumour and a further patient with
an adenocarcinoma within a vestigial urachal tract below the
umbilicus and 12 metastatic cancers were diagnosed and the
histological diagnoses are shown in Table 6.
4. Discussion
397 patients referred under the 2ww rule were reviewed
in the sarcoma fast-track clinic of CUHFT. Approximately
every sixth (17.4%) patient coming through the 2ww fast-
track clinic was diagnosed with cancer. 4.5% were diagnosed
with another primary malignancy and 3% with metastatic
cancers. Every tenth patient (9.82%) was diagnosed with a
primary soft tissue or bone sarcoma.These figures are similar
to recently published 2ww outcome reviews, including the
more detailed work of Barwick et al. [6]. The Improving
Outcomes Guidance for Sarcoma states that “only one in ten
referrals of suspicious lumps will be a sarcoma,” and our
practice confirmed this figure.
The final diagnosis was obtained by histological sampling
in more than half (52.4%) of the patients reviewed, reflecting
a doubt about the nature of the lesions after radiological
imaging. This data is consistent with appropriate referrals
being made by primary care physicians.
Only 3.84% of locally established final diagnosis was sar-
coma, while almost half (44.06%) of supraregional referrals
yielded a sarcoma diagnosis. These figures clearly demon-
strate that the local MDT was efficient in channeling sus-
pected sarcoma patients with a high or moderate suspicion
of sarcoma to the appropriate supraregional service for safe
tissue sampling. In addition, in all patients with a locally
established sarcoma diagnosis the biopsy was performed in
agreement with the supraregional centre.
It has long been recognised that any soft tissuemass larger
than 5 cm holds a significantly higher chance of being malig-
nant [7–9]. 5- and 10-year survival rates dramatically drop
for nonmetastatic sarcomas larger than 5 cm at presentation,
with significant decrease in survival for every incremental
5 cm increase in size [10]. In a more recent series [11] the
average size of sarcomas of those referred under the 2ww
rule was actually slightly higher (10.1 cm versus 9.3 cm) than
for those referred routinely (𝑝 = 0.28). In a comprehensive
review of trends in presentation of bone and soft tissue
sarcomas [12], the size of bone sarcomas had not changed
over time but there had been a slight decrease in the size
of soft tissue sarcomas (10.3 cm before 2000 versus 9.6 cm
after 2000, 𝑝 = 0.03). In our own series the mean size
of the 41 sarcomas diagnosed was 10.6 cm. At presentation
only 6 sarcomas were smaller than 5 cm and 14 sarcomas
were in the 5–10 cm range. Half (21/39) of the sarcomas were
larger than 10 cm. 22 sarcomas were high grade at diagnosis,
which is an unfavourable prognostic factor of its own. Seven
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Table 4: Diagnosed sarcomas according to tumour type, grade, and metastatic nature.
Diagnosis (number) Age (range) Size mm (range) G? G1 G2 G3 M(P) M(E)
Chondrosarcoma (1) 60 90 1
Ewing’s sarcoma (3) 20.33 (17–22) 106.66 (80–140) 3 2
Undifferentiated (pleomorphic) sarcoma (6) 69.33 (40–89) 80.33 (40–130) 6 3 1
Leiomyosarcoma (3) 57.66 (30–70) 80 (45–150) 1 1 1
Liposarcoma (13) 66.61 (34–93) 137.38 (64–240) 3 8 2
Myxoid liposarcoma (1) 69 160 1
Myofibroblastic sarcoma (1) 68 44 1
Myxoid fibrosarcoma (4) 64 (52–81) 80.25 (60–100) 2 2 2
Osteoblastic osteosarcoma (1) 33 110 1 1
PEComa (1) 58 74 1
Sarcoma with rhabdomyosarcomatous differentiation (1) 60 180 1 1
Spindle cell sarcoma (3) 65 (26–85) 108.33 (10–220) 1 2
Synovial sarcoma (1) 53 40 1
Gastrointestinal stromal tumour (2) 58.5 (54–63) 150 (100–200) 2 1
G?: radiological diagnosis only and therefore grade is unknown, G1: grade 1, G2: grade 2, G3: grade 3, M(P): metastatic at presentation, and M(E): early (<1
year) metastatic relapse.
Table 5: Therapeutic approach and management of the sarcoma patients diagnosed in the 2ww clinic.
Curative Palliative Died
Surgery Surgery + Tx Chemo/Rad Rad Chemo BSC
Chondrosarcoma (1) 1
Ewing’s sarcoma (3) 1 2
Undifferentiated (pleomorphic) sarcoma (6) 1 2 1 2 2
Leiomyosarcoma (3) 3
Liposarcoma (13) 6 2 5 3
Myxoid liposarcoma (1) 1
Myofibroblastic sarcoma (1) 1
Myxoid fibrosarcoma (4) 1 3
Osteoblastic osteosarcoma (1) 1 1
PEComa (1) 1
Sarcoma with rhabdomyosarcomatous differentiation (1) 1 1
Spindle cell sarcoma (3) 1 1 1 1
Synovial sarcoma (1) 1
GIST (2) 1 1
Tx: perioperative neoadjuvant/adjuvant radio- and/or chemotherapy, Chemo: chemotherapy, Rad: radiotherapy, BSC: best supportive care, PEComa:
perivascular epithelioid cell tumour, and GIST: gastrointestinal stromal tumour.
patients had distant spread of disease at presentation, further
3 developing metastatic disease within 1 year of primary
diagnosis (Table 4). In 10/39 sarcoma cases the therapeutic
approach was palliative from the very beginning, 6 patients
being unsuitable for any active treatment because of poor
performance status and comorbidities. While only two and
a half years have elapsed since the very beginning of the
study entry, 8 sarcoma patients have already died since their
diagnosis.
The overall size of 10.6 cm is more than double the
size indicated in the national guidelines previously quoted.
Our results contribute to the gradually increasing body
of scepticism regarding the effectiveness of the easy-access
2ww fast-track diagnostics to meet their primary aim of
diagnosing sarcomas early [6, 11, 13, 14].There is concern that
as a consequence of running such continuously expanding
clinics, trained personnel andfinancial resources are removed
from the highly specialised care of patients already diagnosed
with sarcoma.
While ultrasonography was suggested to be less reliable
thanmagnetic resonance imaging for further investigation of
soft tissue masses [15], it was found to be an effective diag-
nostic triage tool for the evaluation of soft tissue mass cases
referred from primary care [16]. Imaging triage of soft tissue
masses proved to be safe and reliable in detecting benign
lumps while increasing the proportion of indeterminate and
malignant lesions cases referred to specialist centres [17]. In
our own series the proportion of benign tumours was high;
almost half (48.4%) of the patients were diagnosed with a
benign growth. Nevertheless, in 64 cases (Table 3) ultrasound
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Table 6: Nonsarcomatous cancer diagnosis.
Metastatic cancer
Breast cancer 2
Colorectal cancer 1
Lung cancer 3
Renal cell carcinoma 2
Transitional cell carcinoma 1
Paraganglioma 1
Squamous cell carcinoma (skin) 1
Nonseminomatous germ cell tumour 1
Primary cancer
Classical Hodgkin’s lymphoma 1
Cutaneous marginal zone lymphoma 1
Follicular lymphoma 3
High grade B-cell lymphoma 1
Anaplastic large cell lymphoma 1
Mantle cell lymphoma 1
Plasmacytoma 5
Myeloma 1
Merkel cell carcinoma 1
Urachal adenocarcinoma 1
on its ownwas a useful imaging tool to lead to a final diagnosis
of a benign lesion. Our study supports recommendations [11,
14] that patients with suspicious lumps should be investigated
by ultrasound prior to a 2ww referral. Our belief and advice
is that this should be done by a radiologist with expertise in
musculoskeletal radiology.
Themost recent 2015 NICE guidelines [18] have reviewed
the lack of evidence with regard to reliable alarm symptoms
and signs in the early diagnosis of sarcomas. No specific
symptoms have exceeded the above 3% positive predictive
value threshold in the diagnosis of either bone or soft tissue
sarcomas, and therefore none of the five classical alarming
sarcoma symptoms were included as a 2ww referral criteria.
Recommendations have been made for suspected cancer
pathway referral from primary care in the case of a suspicious
radiographic result (bone sarcomas) or ultrasound result (soft
tissue sarcomas) [18]. These guidelines by default render
much more freedom to the GPs in evaluating sarcoma alarm
symptoms in the community and decrease the burden of
referrals toward tertiary centres. It can be argued that these
new guidelines also hold an inherent risk of leading tomissed
sarcoma diagnosis due to the relative lack of exposure to
musculoskeletal radiology of community ultrasonographers.
We also need to ensure that the awareness of the classical
sarcoma alarm symptom “quintet” does not get forgotten by
primary care physicians.
The Independent Cancer Task Force in their next 5-year
vision paper listed a national ambition of achieving earlier
diagnosis of cancer as part of their six key priorities [19].They
propose a shift towards faster and less restrictive investigative
testing and giving GPs direct access to key investigative tests.
The task force encourages the testing of new models, which
could reduce the burden and expectation on GPs.
The large group of sarcomas encompassing more than 80
different histotypes are varied in their biological behaviour
and anatomical location of origin affecting the whole body
(often mimicking the symptoms of a wide variety of other
solid tumours), thus rendering the early diagnosis of this
specific tumour type potentially difficult. As reflected in this
study, we believe that, based on the complex investigational
pathways and spectra of established diagnoses in a sarcoma
diagnostic practice, these services strongly enhance the gen-
eral diagnostic skills of the oncologists involved. We suggest
that each cancer centre involved in the teaching of the future
generation of both surgical and nonsurgical oncologists may
consider setting up such practices regardless of the level of
their involvement in the management of sarcomas.
5. Conclusion
We have achieved the targets outlined in the Improving
Outcomes Guidance for Sarcoma document with a 10%
diagnosis rate of sarcoma. However, our results suggest
that there is little evidence that the two-week wait clinic
is achieving the task of diagnosing sarcomas at an earlier
and more treatable stage. There is genuine concern that
by running such continuously expanding clinics, trained
personnel and financial resources are removed from the
highly specialised care of patients already diagnosed with
sarcoma. Sarcoma diagnostic clinics yet still offer an excellent
template of enhancing diagnostic skills of all cancer types and
thus involvement in its work could be usefully integrated into
oncology training curricula.
A consensus of sarcoma experts on national and interna-
tional levels is needed to provide clear guidance in regard to
improving services nationally for a genuinely early diagnosis
of bone and soft tissue sarcomas.
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